Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.81 |
| ▸ | F10 | P00742 | 2/20 | 0.81 |
| ▸ | F7 | P08709 | 2/20 | 0.81 |
| ▸ | METAP2 | P50579 | 7/20 | 0.58 |
| ▸ | METAP1 | P53582 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CBFB | Q13951 | 9/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30385750 | 0.99 | F2 (0.79) | F2F10F7METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL23201161 | 0.99 | F2 (0.79) | F2F10F7METAP2METAP1 | |
| SCHEMBL7371342 | 0.90 | F2 (1.00) | F2F10F7METAP2METAP1 | |
| SCHEMBL29517866 | 0.87 | CHEK2 (0.67) | F2F10F7METAP2METAP1 | |
| SCHEMBL179156 | 0.87 | CHEK2 (0.67) | F2F10F7METAP2METAP1 | |
| SCHEMBL7409967 | 0.86 | F10 (0.60) | F2F10F7PLAUPRSS1 | |
| SCHEMBL2077857 | 0.86 | F2 (0.60) | F2F10F7KMT2AGAA | |
| SCHEMBL7402927 | 0.85 | F2 (0.62) | F2F10F7METAP2METAP1 | |
| SCHEMBL7402924 | 0.85 | F2 (0.59) | F2F10F7METAP2METAP1 | |
| SCHEMBL7406189 | 0.83 | F2 (0.57) | F2F10F7PLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-0943008-B1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6355460-B1 | DETECTING ENZYME INHIBITORS; INCUBATE ENZYME WITH MODULATOR, MONITOR SAMPLE FOR REDUCTION IN ENZYME ACTIVITY, REDUCTION IN ENZYME ACTIVITY INDICATES MODULATOR | AXYS PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | disclosed |
| US-6255091-B1 | ASSAYING FOR ENHANCED INHIBITION OF SERINE PROTEASE IN A MEDIUM THAT IS DEVOID OF DISSACIATED DIVALENT METAL CATIONS | AXYS PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0943008-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022619-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F2 4188/4885F10 4171/4885F7 4785/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4188/4885F10 4171/4885F7 4785/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | F2 36/4885F10 299/4885F7 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.